Do GLP-2 and Dual GIP/GLP-1 Agonists Require the Same Characterization as GLP-1 Analogs for ANDA?
Introduction: The landscape of incretin-based therapies has expanded far beyond the first-generation GLP-1 receptor agonists. Regulatory submissions for GLP-2 and […]






